Discrimination analysis of mass spectrometry proteomics for ovarian cancer detection

Acta Pharmacologica Sinica

Volumn 29, Issue 10, 2008, Pages 1240-1246

  Hong, Yan Jun ^a   Wang, Xiao Dan ^a   Shen, David ^b   Zeng, Su ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Alps Biostatistics Services LLC   (United States)

Author keywords

Discrimination analysis; Mass spectrometry; Ovarian cancer; Proteomics

Indexed keywords

MOLECULAR MARKER;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLUSTER DISCRIMINATION METHOD; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG DISCRIMINATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MATHEMATICAL COMPUTING; OVARY CANCER; PROBABILITY; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

ALGORITHMS; FEMALE; HUMANS; MASS SPECTROMETRY; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTEOMICS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 53749103211     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00861.x     Document Type: Article

References (18)

1. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 2003 425 : 905.
2. Rai AJ, Chan DW. Cancer proteomics: Serum diagnostics for tumor marker discovery. Ann N Y Acad Sci 2004 1022 : 286 94.
3. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems. J Natl Cancer Inst 2004 96 : 353 6.
4. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005 97 : 315 9.
5. Colantonio DA, Chan DW. The clinical application of proteomics. Clin Chim Acta 2005 357 : 151 8.
6. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004 3 : 367 78.
7. Aebersold R. Mann M. Mass spectrometry-based proteomics. Nature 2003 422 : 198 207.
8. Pusch W, Flocco MT, Leung S, Thiele H, Kostrzewa M. Mass spectrometry-based clinical proteomics. Pharmacogenomics 2003 4 : 463 76.
9. Diamandis EP, van der Merwe D. Plasma protein profiling by mass spectrometry for cancer diagnosis: Opportunities and limitations. Clin Cancer Res 2005 11 : 963 5.
10. Soltys SG, Le QT, Shi G, Tibshirani R, Giaccia AJ, Koong AC. The use of plasma surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers. Clin Cancer Res 2004 10 : 4806 12.
11. Gramolini AO, Peterman SM, Kislinger T. Mass spectrometry-based proteomics: a useful tool for biomarker discovery Clin Pharmacol Ther 2008 83 : 758 60.
12. Petricoin E III., Ardekani A, Hitt B, Levine P, Fusaro V, Steinberg S, et al. Use of proteomic patterns in serum to identify ovarian cancer. The Lancet 2002 359 : 572 7.
13. Banks RE, Stanley AJ, Cairns DA, Barrett JH, Clarke P, Thompson D, et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 2005 51 : 1637 49.
14. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Nat Cancer Inst 2005 97 : 307 9.
15. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005 5 : 142 9.
16. White CN, Zhang Z, Chan DW. Quality control for SELDI analysis. Clin Chem Lab Med 2005 43 : 125 6.
17. Wong JW, Sullivan MJ, Cartwright HM, Cagney G. msmsEval: tandem mass spectral quality assignment for high-throughput proteomics. BMC Bioinformatics 2007 8 : 51.
18. Flikka K, Martens L, Vandekerckhovel J, Gevaert K, Eidhammer I. Improving the reliability and throughput of mass spectrometry-based proteomics by spectrum quality filtering. Proteomics 2006 6 : 2086 94.